✅ NHS-sourced information. General health information only — not personal medical advice. Always consult your GP or specialist.

NICE Cancer 20 October 2026

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more lines of anti-HER2 treatment

TA1202

New Guidance: NICE
View official guidance ↗

TA1202

📋 What this means for you: Speak to your GP or specialist to understand how this guidance affects your care.

This article summarises content originally published by NICE. PatientIQ provides independent plain English summaries.

Free health updates

Stay one step ahead
of your condition.

New trial alerts, treatment news, and plain-English updates — matched to your condition. Free forever.

No spam. Unsubscribe anytime. Your data is private.